However, the main hindrances of the present CFTR modulators are related to their limited efficacy in reducing the chronic lung bacterial infection burden and inflammatory response, which are the main causes of the pulmonary tissue damage and progressive respiratory insufficiency that lead to heavy daily therapies, limitations in the quality of life and premature death of pwCF. This evidence concerns the gene CFTR and Respiratory insufficiency.